HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients
Monique C. Minnema,
Kazem Nasserinejad,
Ute Hegenbart,
Paula F. Ypma,
Ka Lung Wu,
Marie Jose Kersten,
Sandra Croockewit,
Sonja Zweegman,
Lidwine Tick,
Annemiek Broijl,
Harry Koene,
Gerard M. J. Bos,
Pieter Sonneveld,
Stefan O. Schönland
Affiliations
Monique C. Minnema
Department of Hematology UMC Utrecht University Utrecht Utrecht The Netherlands
Kazem Nasserinejad
Department of Hematology HOVON Data Center Erasmus MC Cancer Institute Rotterdam The Netherlands
Ute Hegenbart
Department of Hematology and Oncology Amyloidosis Center University Hospital Heidelberg Heidelberg The Netherlands
Paula F. Ypma
Department of Internal Medicine Haga Hospital Den Haag The Netherlands
Ka Lung Wu
Department of HematologyZiekenhuis Netwerk Antwerpen StuivenbergAntwerp Belgium
Marie Jose Kersten
Department of Hematology Amsterdam University Medical Center Amsterdam The Netherlands
Sandra Croockewit
Department of Hematology Radboud University Medical Center Nijmegen The Netherlands
Sonja Zweegman
Department of Hematology Amsterdam University Medical Center Amsterdam The Netherlands
Lidwine Tick
Department of Internal Medicine Máxima Medical Center Eindhoven The Netherlands
Annemiek Broijl
Department of Hematology Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands
Harry Koene
Department of Internal Medicine Antonius Ziekenhuis Nieuwegein The Netherlands
Gerard M. J. Bos
Department of Internal Medicine Division of Hematology Maastricht University Medical Center+ Maastricht The Netherlands
Pieter Sonneveld
Department of Hematology Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands
Stefan O. Schönland
Department of Hematology and Oncology Amyloidosis Center University Hospital Heidelberg Heidelberg The Netherlands
Abstract The HOVON 104 studied bortezomib‐dexamethasone induction therapy and autologous stem cell transplantation in 50 patients, of whom 35 received an autologous stem cell transplantation (ASCT). We demonstrate a 5‐year overall survival (OS) of 73% and progression‐free survival (PFS) of 52% for all 50 patients with a median follow‐up of 61.3 months. For the 35 transplanted patients, calculated from the date of ASCT, the 5‐year OS and PFS were 91% and 68%, respectively. After ASCT, the rate of organ response improved over time but stabilized around 3 years. A complete cardiac response was seen in around 60% of patients and remained stable from 2 years onward. Reaching complete renal response was slower over time and achieved by 61% of the renal‐affected patients at 5 years. We confirm the excellent outcomes after ASCT and demonstrate a 60% complete organ response with longer follow‐up.
